23andme
The deal values 23andMe at approximately $3.5 billion through the combination of stock and cash financing.
Also: Blood glucose monitoring could be coming to next-gen consumer smartwatches; new incubator looking for disruptive health tech startups.
Sequoia Capital and NewView Capital participated in the latest funding round.
While the company's new 510(k) cuts down some of the burden, consumers are still advised to consult their healthcare provider before making any changes to their treatments.
The cuts equal a 14% reduction in the consumer genomic company's workforce.
Also: Khosla heir calls digital health investment a big disappointment; Humana and Philips partner on MA member monitoring.
The DnaNudge pop-ups aim to help Waitrose and John Lewis customers make healthier food choices.
The Israel-based company is offering 11 genetic risk tests, three polygenic risk tests and 15 carrier status reports.
The companies will provide certain consumers an easy-to-understand report describing their recent tests, and may receive another at little to no cost if recommended by a genetic counselor.
Reactions to the news are mixed, with some experts saying the test is unlikely to make much of a difference.